The Goldman Sachs Group Boosts Danaher (NYSE:DHR) Price Target to $270.00

Danaher (NYSE:DHR) had its price target increased by The Goldman Sachs Group from $265.00 to $270.00 in a report released on Tuesday,MarketScreener reports. The firm presently has a “buy” rating on the conglomerate’s stock. The Goldman Sachs Group’s target price suggests a potential upside of 11.62% from the company’s previous close.

A number of other research firms have also recently commented on DHR. Wells Fargo & Company raised their price target on shares of Danaher from $230.00 to $240.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. Morgan Stanley initiated coverage on Danaher in a research report on Monday, December 1st. They issued an “overweight” rating and a $270.00 target price for the company. Bank of America dropped their price target on Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Rothschild Redb cut Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Finally, HSBC upped their target price on Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Monday, December 1st. Twenty analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $252.09.

Danaher Trading Up 3.2%

NYSE DHR opened at $241.90 on Tuesday. The stock has a market capitalization of $170.86 billion, a P/E ratio of 49.88, a P/E/G ratio of 4.17 and a beta of 0.89. The business has a 50 day simple moving average of $229.62 and a 200 day simple moving average of $212.65. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. Danaher has a one year low of $171.00 and a one year high of $258.23.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The firm had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.71 EPS. Research analysts expect that Danaher will post 7.63 earnings per share for the current year.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Georgeann Couchara sold 5,174 shares of Danaher stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares of the company’s stock, valued at $552,352.50. The trade was a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Teri List sold 3,298 shares of the company’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the sale, the director owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. The trade was a 13.71% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 30,248 shares of company stock worth $6,609,663. Corporate insiders own 11.10% of the company’s stock.

Hedge Funds Weigh In On Danaher

Several hedge funds have recently modified their holdings of the company. Baker Ellis Asset Management LLC bought a new position in shares of Danaher in the fourth quarter valued at approximately $211,000. Jackson Square Capital LLC boosted its position in Danaher by 0.6% in the fourth quarter. Jackson Square Capital LLC now owns 9,403 shares of the conglomerate’s stock worth $2,153,000 after purchasing an additional 57 shares during the last quarter. Franklin Street Advisors Inc. NC grew its stake in Danaher by 91.7% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 4,485 shares of the conglomerate’s stock valued at $1,027,000 after purchasing an additional 2,145 shares during the period. Ledyard National Bank increased its position in shares of Danaher by 33.7% during the 4th quarter. Ledyard National Bank now owns 7,488 shares of the conglomerate’s stock valued at $1,714,000 after purchasing an additional 1,889 shares during the last quarter. Finally, Townsend Asset Management Corp NC ADV raised its stake in shares of Danaher by 1.1% during the 4th quarter. Townsend Asset Management Corp NC ADV now owns 31,568 shares of the conglomerate’s stock worth $7,227,000 after purchasing an additional 331 shares during the period. Institutional investors own 79.05% of the company’s stock.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Goldman Sachs raised its price target to $270 and kept a Buy rating, signaling institutional confidence and providing upside support for the shares. Goldman Sachs raises price target on Danaher to $270 from $265, maintains Buy rating
• Positive Sentiment: Zacks says Danaher has the setup to beat upcoming earnings (right mix of revenue and margin drivers), which can lift the stock if results beat consensus. Earnings are the immediate catalyst investors are watching. Danaher expected to beat earnings estimates
• Neutral Sentiment: Feature pieces note a “price target reset” and a reframing of Danaher’s story for investors — these can shift investor narratives but are not definitive buy/sell triggers on their own. Why Danaher (DHR) Price Target Reset Is Shaping A New Story For Investors
• Neutral Sentiment: Danaher is scheduled to report quarterly results imminently — that timing is the key near-term event that could validate analyst optimism or amplify concerns. Danaher projected to post quarterly earnings
• Neutral Sentiment: Sector/peer rundowns place Danaher’s recent performance in context versus other research tools & consumables names — useful for relative valuation and positioning decisions. Q3 Rundown: Danaher vs other research tools & consumables stocks
• Negative Sentiment: Valuation checks highlight a premium P/E after recent share momentum, suggesting limited upside versus expectations and greater downside risk if growth slows. Danaher valuation check after recent share momentum
• Negative Sentiment: Multiple “3 reasons to avoid DHR” opinion pieces argue risk points and suggest alternatives, which can pressure sentiment among retail and some institutional investors. 3 reasons to avoid DHR and 1 stock to buy instead 3 Reasons DHR is Risky and 1 Stock to Buy Instead

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.